Cris Loiren Rodriguez

Array ( [id] => 17124454 [patent_doc_number] => 20210299222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/116722 [patent_app_country] => US [patent_app_date] => 2020-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27217 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17116722 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16915873 [patent_doc_number] => 20210188965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP [patent_app_type] => utility [patent_app_number] => 17/115906 [patent_app_country] => US [patent_app_date] => 2020-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40659 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17115906 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16915872 [patent_doc_number] => 20210188964 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => Solution Formulations of Engineered Anti-IL-23p19 Antibodies [patent_app_type] => utility [patent_app_number] => 17/114754 [patent_app_country] => US [patent_app_date] => 2020-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12153 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17114754 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17198696 [patent_doc_number] => 20210338790 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => INTERLEUKIN-13 RECEPTOR ALPHA 2 PEPTIDE-BASED BRAIN CANCER VACCINES [patent_app_type] => utility [patent_app_number] => 17/109463 [patent_app_country] => US [patent_app_date] => 2020-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50993 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17109463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16899067 [patent_doc_number] => 20210177983 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => SINGLE CHAIN Fc FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 17/107450 [patent_app_country] => US [patent_app_date] => 2020-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18117 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17107450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17141718 [patent_doc_number] => 20210309730 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => MULTISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/105181 [patent_app_country] => US [patent_app_date] => 2020-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29101 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 233 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17105181 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16915869 [patent_doc_number] => 20210188961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => ANTI-INTERLEUKIN-23 P19 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/097496 [patent_app_country] => US [patent_app_date] => 2020-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26209 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 190 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17097496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16948171 [patent_doc_number] => 20210206862 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => ANTI-IL-6 RECEPTOR ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/097298 [patent_app_country] => US [patent_app_date] => 2020-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57100 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17097298 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806136 [patent_doc_number] => 20210128689 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING ALLERGIC DISORDERS [patent_app_type] => utility [patent_app_number] => 17/072358 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17072358 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19210735 [patent_doc_number] => 11999783 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-04 [patent_title] => Method of treating autoimmune disease with antibodies against IL-33 [patent_app_type] => utility [patent_app_number] => 17/071046 [patent_app_country] => US [patent_app_date] => 2020-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 9 [patent_no_of_words] => 12920 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17071046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18666281 [patent_doc_number] => 11773159 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same [patent_app_type] => utility [patent_app_number] => 17/036602 [patent_app_country] => US [patent_app_date] => 2020-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 18 [patent_no_of_words] => 115263 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17036602 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710430 [patent_doc_number] => 20210077577 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => BLOCKADE OF CCL18 SIGNALING VIA CCR6 AS A THERAPEUTIC OPTION IN FIBROTIC DISEASES AND CANCER [patent_app_type] => utility [patent_app_number] => 17/034136 [patent_app_country] => US [patent_app_date] => 2020-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37435 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17034136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18013330 [patent_doc_number] => 11505612 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-22 [patent_title] => Method of treating diseases using an IL-17 receptor antibody formulation [patent_app_type] => utility [patent_app_number] => 17/015029 [patent_app_country] => US [patent_app_date] => 2020-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 16 [patent_no_of_words] => 111863 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 233 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17015029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20803730 [patent_doc_number] => 12668626 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-30 [patent_title] => Anti-IL31 antibodies for veterinary use [patent_app_type] => utility [patent_app_number] => 17/638372 [patent_app_country] => US [patent_app_date] => 2020-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 11790 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17638372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711939 [patent_doc_number] => 20210079086 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => Use of Brazikumab to Treat Crohn's Disease [patent_app_type] => utility [patent_app_number] => 16/999470 [patent_app_country] => US [patent_app_date] => 2020-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20890 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16999470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16824259 [patent_doc_number] => 20210139552 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 16/998597 [patent_app_country] => US [patent_app_date] => 2020-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 112275 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16998597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506198 [patent_doc_number] => 20200385454 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => Safe and Effective Method of Treating Psoriasis with Anti-IL23 Specific Antibody [patent_app_type] => utility [patent_app_number] => 16/992628 [patent_app_country] => US [patent_app_date] => 2020-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26280 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16992628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19675921 [patent_doc_number] => 12187771 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-07 [patent_title] => Method of producing Th9 T-cells [patent_app_type] => utility [patent_app_number] => 16/988460 [patent_app_country] => US [patent_app_date] => 2020-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 19759 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16988460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16557214 [patent_doc_number] => 20210002362 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => IL-21 BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/937121 [patent_app_country] => US [patent_app_date] => 2020-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21924 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16937121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17776596 [patent_doc_number] => 20220242945 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 17/620026 [patent_app_country] => US [patent_app_date] => 2020-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37400 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17620026 [rel_patent_id] =>[rel_patent_doc_number] =>)